Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration program, is a virtual event that showcases all there is to know about neovascular, exudative, and degenerative eye diseases. (Adobe Stock image)

Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration program, now in its 20th iteration, is a virtual event scheduled for February 10-11 that showcases all there is to know about neovascular, exudative, and degenerative eye diseases.

The presenters are all experts in their field from renowned institutions worldwide.

“The program will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular age-related macular edema, macular edema, diabetic retinopathy, retinopathy of prematurity, and inherited retinal degenerations with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare,” according to the course co-directors Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD, all from the Bascom Palmer Eye Institute, University of Miami, Miami.

The course is designed for retina specialists, general ophthalmologists, and researchers, and will review the latest advances in imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology.

“We will emphasize early phase clinical trials and recently completed studies focused on the treatment of a wide range of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, uveitis, and retinal degenerations,” the co-directors explained.

Course Program

Friday, February 10

The following are the general topics covered in both sessions. All times are Eastern Standard Time.

7:50 am

Welcome and Overview, Pre-Program Test

8:00-9:30 am

Session I: Non-Exudative AMD

9:30-10:50 am

Session II: Predicting Disease Progression in Non-Exudative AMD

10:50 am-12:30 pm

Session III: Therapies for Non-Exudative AMD

12:30-1:40 pm

Session IV: Pegcetacoplan Results for the Treatment of GA: Derby and Oaks Trials

1:40-2:10 pm

Session V: Panel Discussion on Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD

2:10-4:05 pm

Session VI: Exudative AMD

Saturday, February 11

7:50 am

Welcome and Overview

8:00-9:50 am

Session VII: Session VII: Emerging and Current Therapies for Exudative AMD

9:50 am-12:00 pm

Session VIII: Diabetic Retinopathy-Imaging and Treatment

12:00-12:40 pm

Session IX: Faricimab in Retinal Vascular Diseases

12:40-2:00 pm

Session X: Retinal Vascular Diseases and Uveitis

2:00-2:50 pm

Session XI: Inherited Retinal Degenerations

When participants finish this course, they should be able to:

• Examine new evidence for understanding the pathophysiology in nonexudative age-related macular degeneration
• Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration
• Evaluate emerging therapies for the treatment of nonexudative age-related macular degeneration with a particular focus on complement inhibitors and the population most likely to benefit once these drugs are approved
• Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration
• Evaluate the clinical use of available anti-VEGF drugs for exudative ocular diseases
• Provide an update on the next generation of anti-VEGF therapies recently approved and currently in development
• Evaluate the benefits and limitations of different imaging technologies in the diagnosis and clinical management of macular and retinal diseases and
• Incorporate the latest advances in artificial intelligence, specifically machine learning, for the diagnosis and treatment of retinal diseases

Participants can register for the meeting online.